Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Donald Durden
University of California, San Diego, Department: Pediatrics
Should you be removed from our database? Contact us at [email protected]. Read more below.
SignalRX Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Durden is a co-founder of SignalRX Pharmaceuticals (SignalRX), on the Board of Directors, member of the Scientific Advisory Board and holds (b)(4) equity in the company valued between (b)(4). SignalRX is focused on developing anticancer treatments based on blocking cell signaling pathways. SignalRX’s most advanced program is on the PI-3 kinase pathway. This project is to advance the preclinical development and validation of dual PI-3K/BRD4 inhibitor, SF2523 or its derivative as a final drug candidate against PI-3K/MYC-driven malignancies.
Dual PI3K/BRD4 inhibitory chemotype for maximum inhibition of Myc and cancer
The planned research is relevant to public health because data we and others have acquired shows that our proposed grant to develop the first potent PI3 kinase-BRD4 dual inhibitor to target MYC oncogenesis in cancer cells. Moreover, the proposal is designed to produce a platform technology for the development of dual small molecule inhibitors of PI3K combined with inhibitors of other targets, thereby having a broad impact on public health. Thus the proposed research which will involve a close collaboration between academia and industry is relevant to the part of the NIH?s mission that pertains to the development of new therapeutics able to reduce the burden of human disability via improved treatment of adult and childhood cancer.
Filed on March 26, 2018.
Tell us what you know about Donald Durden's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Donald Durden filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Donald Durden | University of California, San Diego | Conflict of Interest | SignalRX Pharmaceuticals | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.